18 November2026: mAbxience and OncoPrecisionannounce manufacturing and investment agreement for ONC001
mAbxience, a wholly owned subsidiary of Fresenius, entered into an investment, development and manufacturing agreement with OncoPrecision for ONC001, an investigational CD64-targeted ADC. mAbxience will support antibody development from cell line development through process and analytical development and manufacture GMP-grade material for the planned phase I clinical trial
ONC001 is advancing toward first-in-human phase I studies, following its initial public disclosure at the 2025 American Society of Hematology annualmeeting. no clinical efficacy or safety data have been disclosed, as the candidate remains in preclinical development
ONC001 is being developed for monocytic acute myeloid leukaemia and chronic myelomonocytic leukaemia, aggressive blood cancers with limited effective treatment options and poor prognosis. It aims to selectively eliminate leukemic monocytes and tumour-associated macrophages , potentially addressing disease-driving myeloid cell populations
ONC001 is aCD64-targeted ADC designed to bind CD64-expressing leukemic monocytes and tumour-associated macrophages and deliver a cytotoxic payload to eliminate these cells. the specific antibody construct, payload and linker chemistry have not been disclosed
mAbxience has made a strategic investment in OncoPrecision, with its ceo, joining OncoPrecision’s Board of Directors as an Observer. the partnership provides access to mAbxience’s antibody development, GMP manufacturing and regulatory expertise, strengthening ONC001’s clinical manufacturing readiness and supporting OncoPrecision’s future financing and development plans. financial terms of the investment remain undisclosed